Iomai Corp. (IOMI) Secures Agreement with Merck for Preclinical Studies
Iomai Corporation (Nasdaq: IOMI) today announced it has inked an agreement with Merck & Co. Inc. to conduct proof-of-principle preclinical studies regarding the company’s Iomai needle-free immunostimulant patch. Per the agreement, Merck will have the option to negotiate an exclusive license. The preclinical studies will utilize an undisclosed Merck vaccine. "This agreement with Merck allows us to further evaluate the possible applications of our patch," Stanley C. Erck, president and chief executive officer of Iomai, stated in the press release. "Our immunostimulant patch has the potential to improve the immune response to a wide variety of vaccines, allowing for more…